ArticleFrontiers in toxicology2025
Daflon and Centrum mitigate vancomycin-induced nephrotoxicity in rats by ameliorating oxidative stress, DNA damage, apoptosis, and inflammation.
Article in Frontiers in toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biochanin A ameliorates vancomycin-induced acute kidney injury via modulation of the JAK2/STAT-3/GPX4 axis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vancomycin (VM) is widely used for treating life-threatening infections caused by Gram-positive bacteria resistant to other antibiotics. However, its nephrotoxic effects limit clinical use. Objective: This study aimed to evaluate the protective effects of Daflon (DF) and Centrum (CE) against VM-induced nephrotoxicity in male rats. Methods: Fifty healthy male Wistar rats were randomly divided into five groups. Group 1 (negative control) received saline intraperitoneally (IP) for 7 days followed by oral distilled water for 7 days. Group 2 (positive control) received VM (400 mg/kg BW, IP) for 7 days. Group 3 received VM for 7 days followed by DF (100 mg/kg BW, oral) for 7 days. Group 4 received VM for 7 days followed by CE (15 mg/kg BW, oral) for 7 days. Group 5 received VM for 7 days followed by combined DF and CE treatment for 7 days. Blood and kidney samples were collected for hematological, biochemical, molecular, comet assay, and histopathological evaluations. Results: VM administration significantly elevated serum creatinine, urea, and uric acid levels (p < 0.01), increased renal malondialdehyde (MDA), and reduced catalase (CAT) and superoxide dismutase (SOD) activities (p < 0.05). It also induced marked histological changes and increased DNA fragmentation. DF and CE, particularly in combination (Group 5), significantly reduced renal injury, DNA fragmentation, and histopathological alterations. The protective effect followed the order: G5 > G4 > G3 > G2. Furthermore, VM upregulated Conclusion: DF and CE attenuated VM-induced nephrotoxicity through antioxidant, anti-inflammatory, and DNA-protective mechanisms. Their combination provided superior renal protection by reducing oxidative stress, inflammation, and apoptosis, while enhancing antioxidant defenses and DNA repair capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.